Literature DB >> 21765168

Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's).

F O Henes1, Y Chen, T A Bley, M Fabel, M Both, K Herrmann, E Csernok, W L Gross, F Moosig.   

Abstract

OBJECTIVES: To investigate the correlation of serum levels of high mobility group box 1 (HMGB1) with the extent of granulomatous inflammation in granulomatosis with polyangiitis (GPA).
METHODS: From 169 patients with GPA, 17 patients with granulomatous inflammation, without evidence of vasculitis were identified and 36 patients without measurable 'granuloma' formation. HMGB1 serum levels were determined and compared between the two groups, using a Mann-Whitney U test. Serum levels of 26 healthy individuals served as controls. In a further 21 patients with GPA with a pulmonary granulomatous manifestation from the study population, CT volumetry of 'granuloma' was performed. Volumes were compared with serum levels of HMGB1 (Spearman rank order test).
RESULTS: Serum levels of HMGB1 were significantly higher in patients with predominant granulomatous disease than in patients without measurable 'granuloma' manifestations (6.44 ± 4.53 ng/ml vs 3.85 ± 2.88 ng/ml; p=0.0107). In both groups, levels of HMGB1 were significantly higher than in controls (2.34 ± 2.01 ng/ml; p<0.01). A positive correlation of HMGB1 serum levels with volumes of pulmonary 'granuloma' (r=0.761, p<0.0017) was seen.
CONCLUSIONS: HMGB1 serum levels are significantly higher in GPA with predominant granulomatous manifestations and correlate with volumes of pulmonary 'granuloma'. HMGB1 may be used as a marker of the burden of granulomatous inflammation in GPA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21765168     DOI: 10.1136/ard.2010.146456

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

Review 1.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 3.  Biomarkers in connective tissue diseases.

Authors:  Neelakshi R Jog; Judith A James
Journal:  J Allergy Clin Immunol       Date:  2017-12       Impact factor: 10.793

Review 4.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

Review 5.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

6.  Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?

Authors:  A W S de Souza; W H Abdulahad; P Sosicka; J Bijzet; P C Limburg; C A Stegeman; M Bijl; J Westra; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 7.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 8.  Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus.

Authors:  Fleur Schaper; Johanna Westra; Marc Bijl
Journal:  Mol Med       Date:  2014-03-13       Impact factor: 6.354

9.  High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.

Authors:  Alexandre W S de Souza; Kornelis S M van der Geest; Elisabeth Brouwer; Frederico A G Pinheiro; Ana Cecília Diniz Oliveira; Emília Inoue Sato; Luis Eduardo C Andrade; Marc Bijl; Johanna Westra; Cees G M Kallenberg
Journal:  Arthritis Res Ther       Date:  2015-06-12       Impact factor: 5.156

10.  The role of high mobility group box chromosomal protein 1 expression in the differential diagnosis of hepatic actinomycosis: a case report.

Authors:  Chuan-Xin Wu; Hui Guo; Jian-Ping Gong; Qi Liu; Hang Sun
Journal:  J Med Case Rep       Date:  2013-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.